Colloton Robert C 4
4 · MICRUS ENDOVASCULAR CORP · Filed Sep 28, 2010
Insider Transaction Report
Form 4
Colloton Robert C
Vice President
Transactions
- Disposition to Issuer
Common Stock
2010-09-27−25→ 0 total - Disposition to Issuer
Stock Option (Right to Buy)
2010-09-27$14.21/sh−16,145$229,420→ 0 totalExercise: $9.19Exp: 2019-05-26→ Common Stock (16,145 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2010-09-27$14.15/sh−40,943$579,343→ 0 totalExercise: $9.25Exp: 2016-01-06→ Common Stock (40,943 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2010-09-27$17.77/sh−57,913$1,029,404→ 0 totalExercise: $5.63Exp: 2015-02-23→ Common Stock (57,913 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2010-09-27$14.15/sh−9,057$128,157→ 0 totalExercise: $9.25Exp: 2016-01-06→ Common Stock (9,057 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2010-09-27$14.21/sh−8,855$125,830→ 0 totalExercise: $9.19Exp: 2019-05-26→ Common Stock (8,855 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2010-09-27$2.36/sh−18,077$42,662→ 0 totalExercise: $21.04Exp: 2017-05-29→ Common Stock (18,077 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2010-09-27$17.77/sh−53,197$945,577→ 0 totalExercise: $5.63Exp: 2015-02-23→ Common Stock (53,197 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2010-09-27$11.98/sh−13,958$167,217→ 0 totalExercise: $11.42Exp: 2018-05-14→ Common Stock (13,958 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2010-09-27$2.36/sh−6,923$16,338→ 0 totalExercise: $21.04Exp: 2017-05-29→ Common Stock (6,923 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2010-09-27$11.98/sh−6,042$72,383→ 0 totalExercise: $11.42Exp: 2018-05-14→ Common Stock (6,042 underlying)
Footnotes (2)
- [F1]Pursuant to the Agreement and Plan of Merger, dated as of July 11, 2010, between Micrus Endovascular Corporation, Johnson & Johnson and Cope Acquisition Corp., each share of common stock held by the reporting person was converted into the right to receive $23.40 in cash, without interest.
- [F2]Pursuant to the Agreement and Plan of Merger, dated as of July 11, 2010, between Micrus Endovascular Corporation, Johnson & Johnson and Cope Acquisition Corp., this stock option was converted into the right to receive an amount in cash per share subject to the stock option equal to the excess of the per share merger consideration of $23.40 over the per share exercise price of such stock option, without interest.